Get the Stockscreener App
12.51
3.13%
0.38
Vor Biopharma Inc stock is traded at $12.51, with a volume of 3.38M.
It is up +3.13% in the last 24 hours and up +24.35% over the past month.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
See More
Previous Close:
$12.13
Open:
$12
24h Volume:
3.38M
Relative Volume:
2.46
Market Cap:
$274.10M
Revenue:
-
Net Income/Loss:
$-112.46M
P/E Ratio:
-7.628
EPS:
-1.64
Net Cash Flow:
$-99.89M
1W Performance:
+52.93%
1M Performance:
+24.35%
6M Performance:
+202.17%
1Y Performance:
-36.05%
1-Day Range:
$11.77
$14.13
1-Week Range:
$7.99
$14.13
52-Week Range:
$2.622
$65.80
Vor Biopharma Inc Stock (VOR) Company Profile
Name
Vor Biopharma Inc
Sector
Industry
Phone
617-655-6580
Address
500 BOYLSTON STREET, BOSTON
Compare VOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
12.51 | 265.78M | 0 | -112.46M | -99.89M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | JP Morgan | Overweight |
| Nov-25-25 | Resumed | Wedbush | Neutral |
| Oct-15-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-24-25 | Upgrade | Stifel | Hold → Buy |
| Jun-30-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-26-22 | Initiated | Wedbush | Outperform |
| Apr-27-22 | Initiated | Goldman | Neutral |
| Dec-17-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-21 | Initiated | Robert W. Baird | Outperform |
| Dec-02-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Mar-03-21 | Initiated | Evercore ISI | Outperform |
| Mar-02-21 | Initiated | Goldman | Sell |
| Mar-02-21 | Initiated | Stifel | Buy |
View All
Vor Biopharma Inc Stock (VOR) Latest News
Vor Biopharma (VOR) Stock Jumps Over 30% After JPMorgan Upgrade: What December 2025’s Rally Really Means for Investors - ts2.tech
Vor Biopharma (VOR) Is Up 45.6% After Telitacicept Phase 3 Win And JPMorgan Nod Has The Bull Case Changed? - Yahoo Finance
Vor Biopharma approves stock option repricing plan - MSN
Vor Biopharma: J.P. Morgan Makes Bull Case After Corporate Actions Slam Stock Price (VOR) - Seeking Alpha
Vor Biopharma (VOR): Valuation Check After Positive Telitacicept Phase 3 Data and Upbeat JPMorgan Coverage - Yahoo Finance
Vor Biopharma’s Recent Developments: Stock Impact Analyzed - StocksToTrade
Biotech stock soars 40% on JPMorgan’s bold call - Rolling Out
Vor Biopharma (VOR) Surges on J.P. Morgan's Bullish Outlook - GuruFocus
Vor Bio stock gains bullish view at J.P. Morgan (VOR:NASDAQ) - Seeking Alpha
Vor Biopharma (VOR) Stock Surges as JPMorgan Just Made a Massive Call on This Biotech - parameter.io
Vor Biopharma’s Telitacicept: A Promising Buy Amidst Valuation Disconnect and Strategic Focus on Unmet Needs - TipRanks
Vor Biopharma Stock Surge: Strategic Move or Short-Lived Spike? - timothysykes.com
Vor Biopharma reprices stock options for employees and executives By Investing.com - Investing.com South Africa
VOR shares rally over 40% in pre-market trade after JPMorgan initiates bullish coverage - MSN
Vor Biopharma (NASDAQ:VOR) Now Covered by Analysts at JPMorgan Chase & Co. - MarketBeat
Vor Biopharma Approves Stock Option Repricing Plan - TipRanks
Vor Biopharma reprices stock options for employees and executives - Investing.com
VOR Shares Rally Over 40% In Pre-Market Trade After JPMorgan Initiates Bullish Coverage - Stocktwits
JPMorgan Initiates Vor Biopharma at Overweight With $43 Price Target - marketscreener.com
Pre Market Movers: XCUR, VOR, MTVA Set The Path - RTTNews
JP Morgan Initiates Coverage on Vor Biopharma (VOR) with Overwei - GuruFocus
Vor Bio jumps as J.P.Morgan initiates with 'overweight' rating - TradingView
Vor Bio initiated with an Overweight at JPMorgan - TipRanks
JPMorgan initiates Vor Biopharma stock with Overweight rating, $43 target By Investing.com - Investing.com South Africa
JPMorgan initiates Vor Biopharma stock with Overweight rating on telitacicept potential - Investing.com
JPMorgan initiates Vor Biopharma stock with Overweight rating, $43 target - Investing.com
Vor Biopharma (NASDAQ:VOR) Expands Innovation In Hematologic Therapy - Kalkine Media
JPMorgan Starts Vor Biopharma, Inc. (VOR) at Overweight - StreetInsider
Profit Review: Will Vor Biopharma Inc stock maintain momentum in 2025 - moha.gov.vn
Vor Biopharma slumps 26%, prices $100M equity at $10 per share - MSN
Will Vor Biopharma Inc. stock maintain momentum in 2025Gold Moves & Capital Efficiency Focused Strategies - Newser
What drives Vor Biopharma Inc stock priceEarnings Surprise Analysis & Superior Capital Trading Plans - earlytimes.in
Is There An Opportunity With Vor Biopharma Inc.'s (NASDAQ:VOR) 49% Undervaluation? - Yahoo Finance
Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Form 424B3 Vor Biopharma Inc. - StreetInsider
Wedbush Predicts Vor Biopharma's Q4 Earnings (NASDAQ:VOR) - MarketBeat
How Vor Biopharma Inc. stock benefits from global expansionLayoff News & Fast Exit and Entry Strategy Plans - BỘ NỘI VỤ
Wedbush Begins Coverage on Vor Biopharma (NASDAQ:VOR) - MarketBeat
Vor Biopharma (VOR) Upgraded to Buy: Here's What You Should Know - sharewise.com
Wedbush Initiates Coverage on Vor Biopharma (VOR) with Neutral R - GuruFocus
Wedbush Boosts Price Target on Vor Biopharma to $9 From $0.40, Keeps Neutral Rating - marketscreener.com
Wedbush Assumes Vor Biopharma, Inc. (VOR) at Neutral - StreetInsider
Vor Biopharma Inc. (VOR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will Vor Biopharma Inc. stock attract more institutional investorsWeekly Trade Review & Capital Efficiency Focused Strategies - newser.com
Why retail investors favor Vor Biopharma Inc. stock2025 Technical Patterns & Free Community Supported Trade Ideas - newser.com
What technical signals suggest for Vor Biopharma Inc. stockQuarterly Profit Summary & Verified Momentum Stock Alerts - newser.com
Combining price and volume data for Vor Biopharma Inc.2025 Big Picture & Technical Confirmation Alerts - newser.com
How currency fluctuations impact Vor Biopharma Inc. stockFed Meeting & Real-Time Buy Signal Alerts - newser.com
Can a trend reversal in Vor Biopharma Inc. lead to recoveryWeekly Trade Summary & Low Risk Growth Stock Ideas - newser.com
Using data models to predict Vor Biopharma Inc. stock movementJuly 2025 Pullbacks & Low Drawdown Momentum Ideas - newser.com
Vor Biopharma Inc Stock (VOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vor Biopharma Inc Stock (VOR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 28 '25 |
Sale |
27.42 |
124,311 |
3,408,230 |
1,055,749 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 30 '25 |
Sale |
25.12 |
24,579 |
617,424 |
779,652 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 27 '25 |
Sale |
28.12 |
90,941 |
2,557,261 |
1,180,060 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 23 '25 |
Sale |
28.01 |
76,880 |
2,153,409 |
1,324,346 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 24 '25 |
Sale |
28.01 |
53,345 |
1,494,193 |
1,271,001 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 20 '25 |
Sale |
29.67 |
92,023 |
2,730,483 |
0 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 21 '25 |
Sale |
28.11 |
25,027 |
703,509 |
1,401,226 |
| Reprogrammed Interchange LLC | 10% Owner |
Oct 17 '25 |
Sale |
30.25 |
25,717 |
777,987 |
1,178,725 |
| Reprogrammed Interchange LLC | 10% Owner |
Oct 20 '25 |
Sale |
30.05 |
11,616 |
349,101 |
1,167,109 |
| Reprogrammed Interchange LLC | 10% Owner |
Oct 21 '25 |
Sale |
30.07 |
200 |
6,015 |
1,166,909 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):